October 2010
Worldwide Biotech;Oct2010, Vol. 22 Issue 10, p6
Trade Publication
The article reports on the progress of the Aganocide compounds being developed by NovaBay Pharmaceuticals Inc. for the treatment and prevention of antibiotic-resistant infections. NovaBay Pharmaceuticals, which is based in Emeryville, California delivered its progress reports at the 50th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy in Boston, Massachusetts. It claimed that the compounds are highly effective against bacteria, including some multi-drug resistant strains, as a result of its preclinical testing.


Related Articles

  • Aganocide compounds studied for use in treating ocular infection.  // Primary Care Optometry News;Sep2011, Vol. 16 Issue 9, p10 

    The article reports that NovaBay Pharmaceuticals is studying aganicide compounds for use in the treatment of ocular infection.

  • NovaBay Prices IPO At $4/Share Gets $20M To Advance Pipeline.  // BioWorld Today;10/29/2007, Vol. 18 Issue 210, p4 

    The article reports on the pricing of an initial public offering (IPO) of 5 million shares of common stock by Emeryville, California-based NovaBay Pharmaceuticals Inc. at $4 per share to gain gross proceeds of $20 million. NovaBay is the fourth biotechnology company that launched an IPO in...

  • The New Germ Busters. Biba, Erin; Klonek, Roman // Wired;Jun2009, Vol. 17 Issue 6, p38 

    The article offers news briefs related to antimicrobial agents. Researchers are testing new bacteria-killers that bypass the molecular pathways used by antibiotics. Researchers at McNeese State University, Lake Charles, Louisiana believe that proteins in the blood of alligators inhibit bacterial...

  • Infection in the compromised host. Gillett, A.P.; Wise, R.; Geddes, A.M. // British Medical Journal;7/29/1978, Vol. 2 Issue 6133, p335 

    Examines the effectiveness of antibiotics in treating infections. Basis of the antibiotic dosage in treating infections; Essentiality of surveillance for the organisms antibiotic sensitivity; Cause of the organisms resistant to antibiotics.

  • Novabay Shares Tank on Impetigo Phase IIb Miss. Shaffer, Catherine // BioWorld Today;11/8/2013, Vol. 24 Issue 216, p1 

    The article reports that the stocks of Novabay Pharmaceuticals Inc. lost 78 cents, or 46.2 percent, to close at 91 cents on November 7, 2013 after it reported the failure of a Phase IIb study of its impetigo candidate, auriclosene. It offers information on the product which is one the company's...

  • Letters.  // BMJ: British Medical Journal (International Edition);06/17/2000, Vol. 320 Issue 7250, p1665 

    Presents several correspondence on medical-related issues. Length of penicillin treatment of streptococcal infections; Why antibiotics should not be used for self limiting illnesses; Treatment of children with sleep disorders.

  • Oral versus intravenous antibiotics for community acquired lower respiratory tract infection... Chan, Robert; Hemeryck, Linda // BMJ: British Medical Journal (International Edition);5/27/95, Vol. 310 Issue 6991, p1360 

    Studies the difference in the outcome between patients treated with oral and intravenous antibiotics for community acquired lower respiratory tract infection. Criteria for the admission of infected patients; Definition of terms; Lack of significant differences between the groups; Shroter...

  • Older Drugs May Be Okay For VRE UTIs. Schieszer, John // Renal & Urology News;Oct2010, Vol. 9 Issue 10, p1 

    The article reports on the similarity in the clinical outcomes between new broad-spectrum antibiotics and old narrow-spectrum antibiotics among patients with vancomycin-resistant Enterococcus (VRE) urinary tract infections (UTIs).

  • The right drug to cure a urinary tract infection. Young, Stephanie // Glamour;Aug95, Vol. 93 Issue 8, p43 

    Reports on the effectiveness of various antibiotics used to clear up uncomplicated urinary tract infections in women. Effectiveness of a three-day treatment regimen.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics